BCYC News and Press, Bicycle Therapeutics plc From 10/06/23

2023-10-06 15:00:00 ET More on the stock market The U.S. Government Shutdown: Not A Crisis SPY Madness: 'Magnificent Seven' Stocks Up An Average 95% YTD While The Average Stock Is Down More Shades Of 2007 Buy-rated dividend stocks for volatility and high rate...

2023-10-05 05:30:00 ET More on Markets As 10-year Treasury yield pushes higher, Wolfe Research calls for 5% by year end Correction could be coming for mega caps - Wells Fargo Berenberg: Get defensive with healthcare, utilities and telecoms BlackRock is overwe...

2023-09-11 15:22:28 ET More on Bicycle Therapeutics Seeking Alpha’s Quant Rating on Bicycle Therapeutics Historical earnings data for Bicycle Therapeutics Financial information for Bicycle Therapeutics Bicycle Therapeutics: Decent Upside Opportunity, M...

2023-09-11 14:19:40 ET Shares of Bicycle Therapeutics (NASDAQ: BCYC) were up 9% as of 1:30 p.m. ET on Monday after the healthcare stock climbed as high as 10.4% earlier in the day. The company's shares are still down more than 8% so far this year. The clinical-stage biotec...

Alignment with U.S. FDA on design of Phase 2/3 registrational trial, to be initiated in 1Q 2024 Innovative study design allows for potential accelerated approval in untreated (first-line) and previously treated (second-line plus) metastatic bladder cancer Conference call and webca...

Bicycle Therapeutics (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced that management will participate in a fireside chat at the Morgan Stanley 21st ...

2023-08-03 13:56:13 ET Bicycle Therapeutics press release ( NASDAQ: BCYC ): Q2 GAAP EPS of -$1.41 misses by $0.39 . Revenue of $11.4M (+160.3% Y/Y) misses by $1.52M . Cash and cash equivalents were $340.4 million as of June 30, 2023, compared to $339.2 million ...

Continued progress across pipeline, including advancing BT8009, BT5528, and BT7480 in ongoing clinical trials; clinical and regulatory updates remain on track for BT8009 in 2H23 Entered into strategic collaborations with Novartis, Bayer, and broadened an ongoing collaboration with DKFZ in...

2023-07-31 19:07:20 ET Summary Bicycle Therapeutics is an intriguing play in the drug development space. Using its fully synthetic short peptides, the company has developed two mid-stage oncology assets that have achieved some results of interest in urothelial / ovarian cancers. ...

Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ®) technology, today announced the closing on Monday, July 17, 2023 of its underwritten public offering of 6,117,...